Company / Current Liabilities
Sarepta Therapeutics Current Liabilities History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Current Liabilities
$1.1B
FY2025
5-year range
$452.7M / $1.1B
FY2021-FY2025
Trend
+49.7%
vs FY2024
Sector context
#23 of 213
Health Care
What the data says
Sarepta Therapeutics's current liabilities of $1.1B is higher than 89% of companies in the Health Care sector (FY2025). Current Liabilities has increased for 9 consecutive years, from $75M in FY2016 to $1.1B in FY2025.
Based on SEC 10-K filings.
$1.1B in FY2025 with a 5-year CAGR of +21.4%. Top quartile in the Health Care sector.
Increased from $654M to $1.1B over the past 2 years.
Health Care sector context is included.
Current Liabilities over time
Growth rates
- 3-Year CAGR
- +20.9%
- 5-Year CAGR
- +21.4%
- 10-Year CAGR
- -
Sector benchmark
-31.0% below sector average
Key checks
Key Insights
- Sarepta Therapeutics's current liabilities has grown for 9 consecutive years.
- 5-year CAGR of +21.4%, indicating consistent growth.
- In FY2025, current liabilities increased 49.7% year-over-year.
- Ranks #23 out of 213 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score -0.70 (distress zone, below 1.8 threshold)
- Negative profit margin: -11.3%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Current LiabilitiesValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $1.1B | +49.7% |
| FY2024 | $731.7M | +11.9% |
| FY2023 | $653.7M | +5.5% |
| FY2022 | $619.6M | +36.9% |
| FY2021 | $452.7M | +8.8% |
| FY2020 | $416.0M | +57.1% |
| FY2019 | $264.8M | +52.4% |
| FY2018 | $173.7M | +96.6% |
| FY2017 | $88.3M | +17.1% |
| FY2016 | $75.4M | +21.1% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026